ACTRN12608000170325
Completed
Phase 2
A Phase II Study to Assess the Effect of Intermittent Androgen Blockade in the Treatment of Advanced Prostate Cancer
Abbott pharmaceuticals Pty Ltd0 sites250 target enrollmentApril 8, 2008
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Prostate cancer
- Sponsor
- Abbott pharmaceuticals Pty Ltd
- Enrollment
- 250
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Prostate cancer requiring commencement of androgen suppression, and likely to be a candidate for an intermittant program.
Exclusion Criteria
- •Prior treatment with hormonal therapy, chemotherapy or biologic response modifiers (other than neoadjuvant hormonal therapy that meets the criteria of 3\.1\.(i)
- •b) Patients presenting with acute or impending cord compression.
- •c) Patients with extensive involvement manifest by a report of ‘superscan’ type uptake pattern.
- •d) History of prior malignancy except for adequately treated basal cell (or squamous cell) skin cancer, or other cancer for which the patient has been disease\-free for at least 5 years.
- •e) Patients with known history of hypersensitivity reaction to either study medication or drugs with a similar structure.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A clinical trial investigating OSI-906 in patients with cancer of thesurface of the ovary and other solid tumorsRecurrent Epithelial Ovarian Cancer and Other Solid TumorsMedDRA version: 14.1Level: LLTClassification code 10049280Term: Solid tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2009-010319-34-ITASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.199
Active, not recruiting
Phase 1
A clinical trial investigating OSI-906 in patients with cancer of the surface of the ovary and other solid tumorsRecurrent Epithelial Ovarian Cancer and Other Solid TumorsMedDRA version: 14.1 Level: LLT Classification code 10049280 Term: Solid tumour System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1 Level: PT Classification code 10066697 Term: Ovarian cancer recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2009-010319-34-GBAstellas Pharma Global Development, Inc.210
Active, not recruiting
Not Applicable
A clinical trial investigating OSI-906 in patients with cancer of the surface of the ovary and other solid tumorsEUCTR2009-010319-34-PLAstellas Pharma Global Development, Inc.199
Active, not recruiting
Not Applicable
A clinical trial investigating OSI-906 in patients with cancer of the surface of the ovary and other solid tumorsRecurrent Epithelial Ovarian Cancer and Other Solid TumorsMedDRA version: 14.1Level: LLTClassification code 10049280Term: Solid tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2009-010319-34-CZAstellas Pharma Global Development, Inc.199
Not yet recruiting
Not Applicable
A pilot study on the effects of intermittent and graded exercise compared to no exercise for optimising health and reducing symptoms in Chronic Fatigue Syndrome (CFS)patients.Chronic Fatigue SyndromeInflammatory and Immune System - Other inflammatory or immune system disordersOther - Conditions of unknown or disputed aetiology (such as chronic fatigue syndrome/myalgic encephalomyelitis)ACTRN12612001241820Suzanne Broadbent60